CO
COYA
Coya Therapeutics, Inc.
$4.48
-1.54%
$106.7M
No data for this timeframe.
Vol
Market Cap$106.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders5 funds
Inst. Value$6.2M
Inst. Activity3 buys / 0 sells
SEC Reports4
Recent Activity
May 12, 2026
SEC
Coya Therapeutics entered into an at-the-market (ATM) equity sales agreement with Leerink Partners LLC, allowing the com
8-K — Impact 4/10
May 7, 2026
earnings_calendar
COYA Q1 2026 Earnings Scheduled — 2026-05-07
Apr 9, 2026
Insider
Pavao Mark H sold 10,000 shares
Director @ $0.00 ($0.00)
Apr 2, 2026
SEC
Coya Therapeutics founder and Executive Chairman Howard Berman resigned effective April 1, 2026, as part of a planned le
8-K — Impact 3/10
Mar 23, 2026
SEC
Coya Therapeutics, Inc. has had a Form S-3 shelf registration become effective, allowing the company to issue unspecifie
EFFECT — Impact 4/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
66,900 shares ($388.0K)
Inst.
MORGAN STANLEY — DOUBLED
53,356 shares ($309.5K)
Price Targets
$15.21
+239.6% upside
Strong Buy
Current $4.48
Low $12.00
Median $15.50
High $18.00
7 analysts
$12.00
$18.00
Analyst Ratings
3Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 5, 2026 | Roth Capital | INITIATE | Buy |
| Apr 10, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 16, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 ▲ +5.4% | $-0.37 — $-0.36 | -1% YoY | 4 |
| Next Q | $-0.39 ▼ -7.3% | $-0.41 — $-0.37 | -200% YoY | 4 |
| Current FY | $-1.48 ▲ +10.1% | $-1.52 — $-1.42 | -16% YoY | 4 |
| Next FY | $-1.73 ▼ -49.4% | $-1.79 — $-1.66 | -17% YoY | 2 |
Latest Reports
NEUTRAL
8-K
4/10
Coya Therapeutics entered into an at-the-market (ATM) equity sales agreement with Leerink Partners LLC, allowing the com
May 12, 2026
NEUTRAL
8-K
3/10
Coya Therapeutics founder and Executive Chairman Howard Berman resigned effective April 1, 2026, as part of a planned le
Apr 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $5.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $388.0K | ADD |
| MORGAN STANLEY | $309.5K | DOUBLED |
| BANK OF AMERICA CORP | $230.7K | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $58.0K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 9, 2026 | Pavao Mark | A | $0.00 |
5 institutional holders with $6.2M total value (1,069,180 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 899,140 | $5.2M | 84.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 66,900 | $388.0K | 6.3% | ADD +92.2% |
| 3 | MORGAN STANLEY | 53,356 | $309.5K | 5.0% | DOUBLED +3398.8% |
| 4 | BANK OF AMERICA CORP /DE/ | 39,784 | $230.7K | 3.7% | DOUBLED +18404.2% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 10,000 | $58.0K | 0.9% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 34,800 | 66,900 | +92.2% | $388.0K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,525 | 53,356 | +3398.8% | $309.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 215 | 39,784 | +18404.2% | $230.7K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 14,000 | 34,800 | +148.6% | $198.4K | 2025-Q3 |
| MORGAN STANLEY | ADD | 800 | 1,525 | +90.6% | $8.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 142 | 215 | +51.4% | $1.2K | 2025-Q3 |
| UBS Group AG | TRIM | 34,089 | 15,127 | -55.6% | $87.0K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 6,740 | 800 | -88.1% | $4.6K | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 33,944 | — | $219.6K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 12,200 | — | $78.9K | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 10,000 | — | $64.7K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 2,800 | 6,740 | +140.7% | $43.6K | 2025-Q1 |
| UBS Group AG | NEW | — | 43,026 | — | $246.5K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 800 | 2,800 | +250.0% | $16.0K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 17,200 | 0 | -100.0% | $0.00 | 2024-Q4 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 9, 2026 | Pavao Mark H | Director | A | 10,000 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.5/10.
NEUTRAL
8-K
4/10
Coya Therapeutics entered into an at-the-market (ATM) equity sales agreement with Leerink Partners L
May 12, 2026
NEUTRAL
8-K
3/10
Coya Therapeutics founder and Executive Chairman Howard Berman resigned effective April 1, 2026, as
Apr 2, 2026
NEUTRAL
EFFECT
4/10
Coya Therapeutics, Inc. has had a Form S-3 shelf registration become effective, allowing the company
Mar 23, 2026
NEUTRAL
S-3
3/10
Coya Therapeutics filed an S-3 shelf registration to register 2,522,727 shares of common stock for r
Mar 16, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 3 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.21 mean target
+239.6% upside
Strong Buy (1.00)
$12.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $4.48 |
| Target Low | $12.00 |
| Target Mean | $15.21 |
| Target Median | $15.50 |
| Target High | $18.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.36 | $-0.37 | $-0.36 | -0.7% | +5.4% | 1↑ 1↓ | $0.0B | -36.3% | 4 |
| Next Q 2026-09-30 |
$-0.39 | $-0.41 | $-0.37 | -200.0% | -7.3% | 1↑ 1↓ | $0.0B | -97.8% | 4 |
| Current FY 2026-12-31 |
$-1.48 | $-1.52 | $-1.42 | -16.1% | +10.1% | 1↑ 1↓ | $0.0B | -70.4% | 4 |
| Next FY 2027-12-31 |
$-1.73 | $-1.79 | $-1.66 | -17.0% | -49.4% | 1↑ 0↓ | $0.0B | 144.2% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.362 | |
| 7d ago | $-0.363 | +0.001 |
| 30d ago | $-0.383 | +0.021 |
| 60d ago | $-0.383 | +0.021 |
| 90d ago | $-0.370 | +0.008 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 5, 2026 | Roth Capital | INITIATE | — | Buy |
| Apr 10, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 21, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 23, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
COYA Q1 2026 Earnings Scheduled — 2026-05-07
Mar 24, 2026
earnings_calendar
COYA Q4 2025 Earnings Before Market Open — 2026-03-24